The risk of endometrial cancer appearance and CYP19 and COMT gene polymorphism;Ryzyko wystȩpowania raka endometrium w kontekście wpływu polimorfizmów genów CYP19 i COMT

Polski Merkuriusz Lekarski

Volumn 22, Issue 129, 2007, Pages 208-210

  Szyłło, Krzysztof ^a   Smolarz, Beata ^a   Romanowicz Makowska, Hanna ^a   Przybyłowska, Karolina ^a   Lewy, Jarosław ^a   Kulig, Bartosz ^a  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

CYP19 and COMT gene; Endometrial cancer; Gene polymorphism; PCR RFLP

Indexed keywords

AROMATASE; CATECHOL METHYLTRANSFERASE; DNA; TUMOR MARKER;

ADENOCARCINOMA; AGED; ARTICLE; BLOOD; CASE CONTROL STUDY; ENDOMETRIUM; ENDOMETRIUM TUMOR; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; AROMATASE; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; DNA; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34047113011     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Ball P., Knuppen R.: Catecholoestrogens (2-and 4-hydroxyoestrogens): chemistry, biogenesis, metabolism, occurence and physiological significance. Acta Endocrinol. Supp., 1980, 232, 1-127.
2. Baxter S.W., Choong D.Y., Eccles D.M. i wsp.: Polymorphic variation in CYP19 and the risk of breast cancer. Carcinogenesis, 2001, 22, 347-352.
3. Berstein L.M., Imyanitov E.N., Suspitsin E.N.: CYP19 gene polymorphism in endometrial cancer patients. J. Cancer Clin. Oncol., 2001, 127, 135-138.
4. Bremond A., Bataillard A., Thomas L. i wsp.: Cancer of the endometrium. French National Federation of Cancer (FNCLCC). Br. J. Cancer, 2001, 84, 31-36.
5. Ferenczy A., Bertrand G., Gelfand M.M. i wsp.: Proliferation kinetics of human endometrium during the normal menstrual cycle. Am. J. Obstet. Gynecol., 1979, 133, 859-867.
6. Henderson B.E., Ross R.K., Pike M.C. i wsp.: Endogenous hormones as a major factor in human cancer. Cancer Res., 1982, 42, 3232-3239.
7. Jonard S., Dewailly D.: Polycystic ovary syndrome: recent genetic contributions. Gynecol. Obstet. Fertil., 2002, 30, 603-609.
8. Lachman H.M., Papolos D.F., Saito T., i wsp.: Human catechol-O-methyl-transferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics, 1996, 6, 243-250.
9. Martucci C.P., Fishman J.: P450 enzymes of estrogen metabolism. Pharmacol. Ther., 1993, 57, 237-257.
10. Means G.D., Mahendroo M.S., Corbin C.J. i wsp.: Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem., 1989, 264, 386-391.
11. Platz E.A., Giovannucci E.: The epidemiology of sex steroid hormones and their signaling and metabolic pathways in the etiology of prostate cancer. J. Steroid Biochem. Mol. Biol., 2004, 92, 237-253.
12. Potischman N., Hoover R.N, Brinton L.A. i wsp.: Reversal of relation between body mass and endogenous estrogen concentrations with menopausal status. J. Natl. Cancer Inst. 1996, 88, 1127-1135.
13. Rose PG. Endometrial carcinoma. N. Engl. J. Med., 1996, 335, 610-619.
14. Simpson E.R.: Role of aromatase in sex steroid action. J. Mol. Endocrinol., 2000, 25, 149-156.
15. Yager J.D., Liehr J.G.: Molecular mechanisms of estrogen carcinogenesis. Annu Rev. Pharmacol. Toxicol., 1996, 36, 203-232.